Literature DB >> 12225443

A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder.

Caroline S Stevenson1, Stephanie Whitmont, Laurel Bornholt, David Livesey, Richard J Stevenson.   

Abstract

OBJECTIVE: This is the first systematic examination of the efficacy of a cognitive remediation programme (CRP) for management of adult Attention Deficit Hyperactivity Disorder (ADHD). The CRP was designed to target problems commonly associated with adult ADHD, namely, attention problems, poor motivation, poor organizational skills, impulsivity, reduced anger control and low self-esteem.
METHOD: In a randomized, controlled trial, a representative sample of adults with ADHD (some medicated, some not) were assigned to either a CRP (n = 22) or a waiting list control (n = 21). The CRP was delivered in an intensive format with eight two-hour, weekly sessions with support people who acted as coaches, and participant workbooks with homework exercises.
RESULTS: Participants who completed the CRP reported reduced ADHD symptomatology (effect size (d) = 1.4), improved organizational skills (d = 1.2) and reduced levels of anger (d = 0.5). Clinically significant improvements in ADHD symptomatology (d = 1.4) and organizational skills (d = 1.3) were maintained one year after the intervention.
CONCLUSIONS: These findings suggest that the CRP provides a practical way of enhancing daily functioning for adults with ADHD.

Entities:  

Mesh:

Year:  2002        PMID: 12225443     DOI: 10.1046/j.1440-1614.2002.01052.x

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  44 in total

1.  Efficacy of meta-cognitive therapy for adult ADHD.

Authors:  Mary V Solanto; David J Marks; Jeanette Wasserstein; Katherine Mitchell; Howard Abikoff; Jose Ma J Alvir; Michele D Kofman
Journal:  Am J Psychiatry       Date:  2010-03-15       Impact factor: 18.112

Review 2.  Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults.

Authors:  Alexandra Philipsen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-09       Impact factor: 5.270

3.  New developments in the treatment of attention-deficit/hyperactivity disorder in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

4.  Adolescents with childhood ADHD and comorbid disruptive behavior disorders: aggression, anger, and hostility.

Authors:  Seth C Harty; Carlin J Miller; Jeffrey H Newcorn; Jeffrey M Halperin
Journal:  Child Psychiatry Hum Dev       Date:  2008-07-03

5.  Altering the Cognitive-Affective Dysfunctions of Psychopathic and Externalizing Offender Subtypes with Cognitive Remediation.

Authors:  Arielle R Baskin-Sommers; John J Curtin; Joseph P Newman
Journal:  Clin Psychol Sci       Date:  2015-01-01

Review 6.  Developmental context and treatment principles for ADHD among college students.

Authors:  Andrew P Fleming; Robert J McMahon
Journal:  Clin Child Fam Psychol Rev       Date:  2012-12

Review 7.  Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder.

Authors:  Laura E Knouse; Steven A Safren
Journal:  Psychiatr Clin North Am       Date:  2010-09

8.  Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review.

Authors:  Jeffery N Epstein; Margaret D Weiss
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-29

9.  Short cognitive behavioral therapy and cognitive training for adults with ADHD - a randomized controlled pilot study.

Authors:  Maarit Virta; Anita Salakari; Mervi Antila; Esa Chydenius; Markku Partinen; Markus Kaski; Risto Vataja; Hely Kalska; Matti Iivanainen
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

10.  Attention deficit hyperactivity disorder in adulthood: diagnosis, etiology and therapy.

Authors:  Alexandra Philipsen; Bernd Hesslinger; Ludger Tebartz van Elst
Journal:  Dtsch Arztebl Int       Date:  2008-04-25       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.